Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remifentanil versus neuromuscular blocker for rapid sequence induction in patients at risk of aspiration
2019-000753-31Phase 3Completed
- Sponsor
- CHU de Nantes
- Start
- May 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of remifentanil in aspiration of vomitus (2 arms), sponsored by CHU de Nantes. Primary endpoint: Primary: Rate of tracheal intubation without major complications. Started May 2019; status: completed.
02
Drugs
remifentanil
03
Conditions
aspiration of vomitus
Beyond the preview
Go deeper on 2019-000753-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000753-31.